Jean Francois Formela - Jun 28, 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
By: /s/ Frank Castellucci, Attorney-In-Fact
Stock symbol
NTLA
Transactions as of
Jun 28, 2021
Transactions value $
-$73,448,879
Form type
4
Date filed
6/29/2021, 09:48 AM
Previous filing
Jun 25, 2021
Next filing
Aug 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$3.3M -26K -4.62% $127.02 537K Jun 28, 2021 See Footnote F1, F2, F20
transaction NTLA Common Stock Sale -$7.1M -55.5K -10.33% $127.79 482K Jun 28, 2021 See Footnote F1, F3, F20
transaction NTLA Common Stock Sale -$7.25M -56.3K -11.68% $128.77 426K Jun 28, 2021 See Footnote F1, F4, F20
transaction NTLA Common Stock Sale -$6.33M -48.7K -11.45% $129.88 377K Jun 28, 2021 See Footnote F1, F5, F20
transaction NTLA Common Stock Sale -$8.69M -66.5K -17.64% $130.79 310K Jun 28, 2021 See Footnote F1, F6, F20
transaction NTLA Common Stock Sale -$7.09M -53.8K -17.34% $131.82 257K Jun 28, 2021 See Footnote F1, F7, F20
transaction NTLA Common Stock Sale -$7.46M -56.2K -21.9% $132.77 200K Jun 28, 2021 See Footnote F1, F8, F20
transaction NTLA Common Stock Sale -$4.89M -36.5K -18.23% $133.77 164K Jun 28, 2021 See Footnote F1, F9, F20
transaction NTLA Common Stock Sale -$4.16M -30.8K -18.82% $134.86 133K Jun 28, 2021 See Footnote F1, F10, F20
transaction NTLA Common Stock Sale -$2.97M -21.9K -16.46% $135.83 111K Jun 28, 2021 See Footnote F1, F11, F20
transaction NTLA Common Stock Sale -$416K -3.03K -2.73% $137.01 108K Jun 28, 2021 See Footnote F1, F12, F20
transaction NTLA Common Stock Sale -$745K -5.4K -5% $138.05 103K Jun 28, 2021 See Footnote F1, F13, F20
transaction NTLA Common Stock Sale -$582K -4.2K -4.09% $138.58 98.5K Jun 28, 2021 See Footnote F1, F14, F20
transaction NTLA Common Stock Sale -$7.32M -52.3K -53.13% $139.96 46.2K Jun 28, 2021 See Footnote F1, F15, F20
transaction NTLA Common Stock Sale -$1.13M -8.03K -17.39% $140.80 38.1K Jun 28, 2021 See Footnote F1, F16, F20
transaction NTLA Common Stock Sale -$1.19M -8.42K -22.09% $141.66 29.7K Jun 28, 2021 See Footnote F1, F17, F20
transaction NTLA Common Stock Sale -$1.94M -13.6K -45.64% $142.88 16.1K Jun 28, 2021 See Footnote F1, F18, F20
transaction NTLA Common Stock Sale -$882K -6.15K -38.08% $143.45 10K Jun 28, 2021 See Footnote F1, F19, F20
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.32 - $127.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.32 - $128.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.32 - $129.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.32 - $130.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 - $131.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.32 - $132.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $132.32 - $133.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $133.32 - $134.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (9) of this Form 4.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $134.32 - $135.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (10) of this Form 4.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $135.32 - $136.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (11) of this Form 4.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $136.32 - $137.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (12) of this Form 4.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $137.32 - $138.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (13) of this Form 4.
F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $138.32 - $139.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (14) of this Form 4.
F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $139.32 - $140.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (15) of this Form 4.
F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $140.32 - $141.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (16) of this Form 4.
F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $141.32 - $142.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (17) of this Form 4.
F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $142.32 - $143.31, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (18) of this Form 4.
F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices from $143.32 - $144.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (19) of this Form 4.
F20 Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney (incorporated by reference to Exhibit 24, Power of Attorney, filed on Form 4 with the SEC on March 13, 2017 by the reporting person)